BeiGene, Ltd. (HKG:6160)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
152.20
+0.70 (0.46%)
Apr 24, 2025, 4:08 PM HKT

BeiGene Company Description

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors.

Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK‑targeting chimeric degradation activation compound active against wild‑type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC.

It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis.

BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

BeiGene, Ltd.
BeiGene logo
Country Cayman Islands
Founded 2010
Industry Biotechnology
Sector Healthcare
Employees 11,000
CEO John Oyler

Contact Details

Address:
94 Solaris Avenue
Camana Bay, KY1-1108
Cayman Islands
Phone 345-949-4123
Website beigene.com

Stock Details

Ticker Symbol 6160
Exchange Hong Kong Stock Exchange
Fiscal Year January - December
Reporting Currency USD
ISIN Number KYG1146Y1017
SIC Code 2836

Key Executives

Name Position
John V. Oyler Co-Founder, Executive Chairman and Chief Executive Officer
Dr. Xiaobin Wu Ph.D. President, Chief Operating Officer and GM of China
Dr. Xiaodong Wang Ph.D. Co-Chairman of Scientific Advisory Board, Non-Executive Director and Co-Founder
Aaron Rosenberg Chief Financial Officer
Chan Lee General Counsel and Senior Vice President
Wang Lai Ph.D. Global Head of Research & Development
Titus B. Ball Vice President and Chief Accounting Officer
Liza Heapes Head of Investor Relations
Yang Ji Chief Compliance Officer
Dr. Yan Qi Senior Vice President and Head of Public Affairs - Greater China